Vor Biopharma (NASDAQ:VOR) Trading Up 17.8% – Time to Buy?

Shares of Vor Biopharma Inc. (NASDAQ:VOR) were up 17.8% during mid-day trading on Thursday . The company traded as high as $20.32 and last traded at $21.6640. 288,239 shares were traded during trading, a decline of 73% from the average session volume of 1,053,732 shares. The stock had previously closed at $18.39.

Analyst Ratings Changes

Several equities research analysts have recently commented on VOR shares. Wells Fargo & Company started coverage on Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 price target on the stock. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Vor Biopharma in a report on Monday, May 18th. Weiss Ratings upgraded Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Finally, Wedbush upped their target price on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Vor Biopharma presently has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Vor Biopharma Price Performance

The company has a 50 day moving average of $15.15 and a 200 day moving average of $14.66.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. Equities analysts predict that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Insider Buying and Selling at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 589,257 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63. Following the sale, the director directly owned 4,555,741 shares of the company’s stock, valued at approximately $75,579,743.19. This trade represents a 11.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 2,742,903 shares of company stock worth $44,672,376. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Vor Biopharma during the 4th quarter valued at $36,000. Bank of America Corp DE increased its holdings in shares of Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after buying an additional 4,144 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Vor Biopharma in the 3rd quarter worth $230,000. BNP Paribas Financial Markets raised its position in shares of Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after buying an additional 5,058 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new position in Vor Biopharma in the third quarter valued at $304,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).